For 25 years, BioMarin has been dedicated to transforming lives through genetic discovery. We develop targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those suffering from rare genetic disease – all through close collaboration with our patients and patient advocates.
We recognize the importance of integrating the patient voice starting at research and development and continuing even after a medicine is approved to best serve the unique needs of each community.
Our dedicated staff covers multiple regions, attends and hosts important events, provides valuable educational resources and works with a broad range of organizations to make sure that the patient’s voice is integrated into the drug development process and beyond.
At BioMarin, we are committed to the development of new therapies for genetic diseases and conditions. Successful clinical trials are required to gain regulatory approval for new medications to advance patient care, as well as to support existing products.
Phenylketonuria (PKU) Clinical Trial Information
BioMarin is conducting a global clinical trial for adolescents with phenylketonuria (PKU) aged 12 to 17 years. Learn about the PEGASUS study to help advance PKU research.Learn More ⌃
BioMarin in the Community
We have partnered closely with numerous patient advocacy organizations and their members to listen to and understand communities, highlight clinical trial opportunities and develop educational materials to build awareness of rare diseases across the world.
For more information please contact BioMarin Medical Information: email@example.com
If you are already participating in a BioMarin clinical trial and wish to report a problem with the study drug or side effect(s), please contact your study doctor as soon as possible, and please email us at firstname.lastname@example.org or email@example.com.